## **PATENTS**



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

09/674,462

Conf. No. 8594

**Applicant** 

Robert Ian Lechler et al.

Filed

May 8, 2001

T.C./A.U.

1600/1644

Examiner

Ilia I. Ouspenski

Title

Immunosuppression by Blocking T-Cell Co-Stimulation Signal 2

Docket No.

10758.105042 REV1019

Customer No.

20786

Mail Stop AMENDMENT Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Sir:

The citation of information on the accompanying Form PTO/SB/08A, "Supplemental Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

A check in the amount of \$630, covering a \$450 extension of time fee and the \$180 information disclosure statement fee, is enclosed herewith. The Commissioner is authorized to charge any underpayment of fees and to credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

05/12/2006 EAYALEW1 00000034 09674462

02 FC:1806

180.00 OP

 $\mathbf{B}\mathbf{v}$ 

Rebecca J. Kaufman

Reg. No. 44,819

Date: May 8, 2006

KING & SPALDING LLP

1180 Peachtree Street, NE, 34th Floor

Atlanta, GA 30309-3521 Tel.: (404) 572-4600

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Substitute 1000 1449A/PTO **SUPPLEMENTAL** INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

1

Sheet

Filing Date First Named Inventor **Group Art Unit** 

**Attorney Docket Number** 

Complete if Known **Application Number** 09/674,462 May 8, 2001 Lechler et al. 1600 / 1644 Examiner Name Ilia Ouspenski

10758.105042 REV 1019

4093337\_1.DOC

		U.S	S. PATENT DOCUMENTS		
Examiner Initials *	Cite No. 1	U.S. Patent Document  Number Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. 1		Number Kind (if kn	Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T <sup>6</sup>
								_

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>				
	AA	Mirenda, V., et al., "Achieving permanent survival of islet xenografts by independent manipulation of direct and indirect T-cell responses," <i>Diabetes</i> , 54(4):1048-1055 (April 2005).					
	AB	Vaughan, A.N., et al., "Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7," <i>Journal of Immunology</i> , 165(6):3175-3181 (September 15, 2000).					

Examiner Signature		Date Considered	
	-		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.